Pemphigoid is classified as an autoimmune disease, meaning the body's immune system is involved in its development. The specific immune processes result in damage at the junction between the skin's outer layer and the underlying tissue, leading to blister formation. This packet does not provide a certified causative gene claim, inheritance pattern, or molecular mechanism for pemphigoid.

Specific diagnostic methods, testing hierarchies, biomarker thresholds, and differential diagnoses for pemphigoid are not certified in this packet. Newborn screening information is also not available in this packet.

Certified foundational therapies, FDA-approved treatments, and patient assistance program information are not available in this packet. Treatment and management coverage for pemphigoid is unknown or uncertified in this packet.

Prognosis and natural history information for pemphigoid are not certified in this packet.

Several certified active trial records are present for pemphigoid. These include a Phase 1b trial of RAY121 in immunological diseases (NCT06371417, sponsored by Chugai Pharmaceutical, recruiting as of 2024), a study examining proteomic and metabolomic profiles of the ocular surface in diverse pathologies including pemphigoid (NCT04198740, sponsored by the Centre hospitalier de l'Université de Montréal, recruiting), and an autoimmune blistering diseases study (NCT02753777, sponsored by the University of Pennsylvania, recruiting). Additional active records include studies on microbiota in gingival scarring pemphigoid and validation of a severity scoring tool in bullous pemphigoid, among others. Active clinical trials for this condition are listed on ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pemphigoid.